Cargando…
Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson's Disease by Oral Administration of Ether Phospholipids: A Preliminary Report
Introduction. Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD). With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades. L-DOPA (1,3,4-dihydroxyalanine) is the most effective dr...
Autores principales: | Mawatari, Shiro, Ohara, Shinji, Taniwaki, Yoshihide, Tsuboi, Yoshio, Maruyama, Toru, Fujino, Takehiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049862/ https://www.ncbi.nlm.nih.gov/pubmed/32148751 http://dx.doi.org/10.1155/2020/2671070 |
Ejemplares similares
-
Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
por: Fujino, Takehiko, et al.
Publicado: (2017) -
Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats
por: Mawatari, Shiro, et al.
Publicado: (2012) -
Plasmalogens, the Vinyl Ether-Linked Glycerophospholipids, Enhance Learning and Memory by Regulating Brain-Derived Neurotrophic Factor
por: Hossain, Md. Shamim, et al.
Publicado: (2022) -
Changes in Phospholipid Composition of Erythrocyte Membrane in Alzheimer's Disease
por: Oma, Shinji, et al.
Publicado: (2012) -
Identification of plasmalogens in Bifidobacterium longum, but not in Bifidobacterium animalis
por: Mawatari, Shiro, et al.
Publicado: (2020)